It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings ...

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. However, when you're an income investor, your ...

Merck & Co. is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical giant.

In a report released yesterday, Umer Raffat from Evercore ISI maintained a Buy rating on Merck & Company (MRK – Research Report). The company’s shares closed yesterday at $89.67. Leverage the ...

Goldman Sachs analyst writes that Merck delivered strong operational performance across the majority of the company's market-leading (Oncology), attractively emerging (PAH), and re-emerging ...

Merck’s recent earnings call revealed that although the company generated worldwide sales of $64.2 billion—a 7% increase over 2023—the company will be temporarily suspending Gardasil shipments to ...

Lusaka [Zambia]/ Mumbai (Maharashtra) [India], January 4: Merck Foundation, the philanthropic arm of Merck KGaA Germany, marks ‘World Cancer Day 2025’ together with Africa’s First Ladies and ...

as the company temporarily paused shipments of a key vaccine into China. Shares of Merck closed 8% lower on Tuesday. The pharmaceutical giant anticipates 2025 sales of $64.1 billion to $65.6 ...